

REMARKS

Claims 17-26 are pending in this application. Claims 1-16 and claims 27-36 are canceled without prejudice pursuant to the restriction requirement. Applicants reserve the right to file timely divisional applications on the non-elected inventions.

Restriction Requirement

Restriction of the claims was required. The claims were separated in the following groups:

- I. Claims 1-3 are drawn to a method for lowering plasma CRP levels comprising administering to a mammal, in need thereof, an effective amount of a dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted alkyl or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition of the dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted alkyl, classified in class 514, subclass 281.
- II. Claims 4-13 are drawn to a method for lowering plasma CRP levels comprising administering to a mammal, in need thereof, an effective amount of a compound of the formula I, classified in class 514, subclass 282.
- III. Claims 14-16 are drawn to a method for lowering plasma CRP levels comprising administering to a mammal, in need thereof, a effective amount of a dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted alkyl, classified in class 514, subclass 281.
- IV. Claims 17-26 are drawn to a method for reducing systemic inflammation comprising administering to a mammal, in need thereof an effective amount of a compound or pharmaceutical composition comprising a compound of formula I, classified in class 514, subclass 282.

Jan-19-2006, 01:15pm From-

PATENT PFIZER ANN ARBOR MI

7346222928

T-591 P.008/008 F-467

USSN: 10/712,859

- 6 -

PC25163A

V. Claims 27 and 28 are drawn to a method of inhibiting proinflammatory cytokine induced CRP production in a mammal, in need thereof, comprising administering to the mammal an effective amount of dialkyl ether, substituted alkyl, substituted aryl-alkyl, substituted dialkyl thioether, substituted dialkyl ketone, substituted alkyl, classified in class 514, subclass 281.

VI. Claims 28-36 are drawn to a method of inhibiting proinflammatory cytokine induce CRP production in a mammal comprising administering to a mammal an effective amount of compound or pharmaceutical composition comprising formula I, classified in class 514, subclass 282.

Applicants elect Group IV for further prosecution. Applicants reserve the right to pursue the remaining claims in divisional or continuation applications.

It is respectfully submitted that the claims have been put in condition for allowance. Notification to this affect is earnestly solicited. The Examiner is encouraged to contact the Applicants' undersigned attorney to discuss this matter if any questions should arise upon further examination of the pending claims:

Respectfully submitted,

Date: January 12, 2006



William R. Boudreaux
Reg. No. 35,796
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1363
Fax (734) 622-1553